Terns Pharmaceuticals Stock Performance
| TERN Stock | USD 4.10 0.04 0.99% |
On a scale of 0 to 100, Terns Pharmaceuticals holds a performance score of 8. The entity has a beta of 1.32, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Terns Pharmaceuticals will likely underperform. Please check Terns Pharmaceuticals' potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Terns Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Terns Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Terns Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.99 | Five Day Return 14.21 | Year To Date Return (27.69) | Ten Year Return (77.71) | All Time Return (77.71) |
Last Split Factor 1000:50 | Last Split Date 2013-11-04 |
1 | Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates | 03/20/2025 |
2 | Disposition of 952 shares by Kuriakose Emil of Terns Pharmaceuticals at 2.4851 subject to Rule 16b-3 | 04/01/2025 |
3 | Tern Trading Down 15.5 percent Whats Next | 04/17/2025 |
4 | Terns Pharmaceuticals, Inc. Shares Sold by Walleye Capital LLC | 04/23/2025 |
5 | Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule ... | 05/02/2025 |
6 | Terns Advances Clinical Programs with Promising Developments TERN Stock News | 05/08/2025 |
7 | Is Terns Pharmaceuticals, Inc. the Low Risk High Reward Stock Set to Triple by 2030 | 05/09/2025 |
8 | BMO Capital Markets Lowers Terns Pharmaceuticals Price Target to 15.00 | 05/14/2025 |
9 | Acquisition by Gordon Carl L of 4676 shares of Terns Pharmaceuticals at 6.85 subject to Rule 16b-3 | 05/16/2025 |
10 | Tema Etfs LLC Invests 442,000 in Terns Pharmaceuticals, Inc. | 05/19/2025 |
11 | Acquisition by Burroughs Amy L. of 1250000 shares of Terns Pharmaceuticals at 7.31 subject to Rule 16b-3 | 06/03/2025 |
12 | Tern Announces Earnings Results | 06/05/2025 |
| Begin Period Cash Flow | 79.9 M |
Terns Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 318.00 in Terns Pharmaceuticals on March 14, 2025 and sell it today you would earn a total of 92.00 from holding Terns Pharmaceuticals or generate 28.93% return on investment over 90 days. Terns Pharmaceuticals is currently generating 0.5426% in daily expected returns and assumes 5.2015% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Terns, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Terns Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Terns Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Terns Pharmaceuticals, and traders can use it to determine the average amount a Terns Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1043
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TERN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.2 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.54 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 8 92% of assets perform better |
Based on monthly moving average Terns Pharmaceuticals is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Terns Pharmaceuticals by adding it to a well-diversified portfolio.
Terns Pharmaceuticals Fundamentals Growth
Terns Stock prices reflect investors' perceptions of the future prospects and financial health of Terns Pharmaceuticals, and Terns Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Terns Stock performance.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 21.56 M | ||||
| Shares Outstanding | 87.34 M | ||||
| Price To Book | 0.99 X | ||||
| Price To Sales | 302.64 X | ||||
| Gross Profit | 1000 K | ||||
| EBITDA | (87.7 M) | ||||
| Net Income | (88.85 M) | ||||
| Cash And Equivalents | 139.81 M | ||||
| Cash Per Share | 5.51 X | ||||
| Total Debt | 1.35 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 23.59 X | ||||
| Book Value Per Share | 3.73 X | ||||
| Cash Flow From Operations | (70.02 M) | ||||
| Earnings Per Share | (1.18) X | ||||
| Market Capitalization | 354.59 M | ||||
| Total Asset | 363.93 M | ||||
| Retained Earnings | (421.48 M) | ||||
| Working Capital | 346.46 M | ||||
About Terns Pharmaceuticals Performance
By examining Terns Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Terns Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Terns Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.5 K | 2.2 K | |
| Return On Tangible Assets | (0.24) | (0.26) | |
| Return On Capital Employed | (0.29) | (0.31) | |
| Return On Assets | (0.24) | (0.26) | |
| Return On Equity | (0.26) | (0.27) |
Things to note about Terns Pharmaceuticals performance evaluation
Checking the ongoing alerts about Terns Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Terns Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Terns Pharmaceuticals is way too risky over 90 days horizon | |
| Terns Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (88.85 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Terns Pharmaceuticals currently holds about 139.81 M in cash with (70.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Terns Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Tern Announces Earnings Results |
- Analyzing Terns Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Terns Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Terns Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Terns Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Terns Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Terns Pharmaceuticals' stock. These opinions can provide insight into Terns Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.